TRCT
CRSP icon

Tower Research Capital (TRC)’s CRISPR Therapeutics CRSP Stock Holding History

Tower Research Capital (TRC)’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$252K Buy
5,298
+2,874
+119% +$152K 0.01% 1437
2025
Q4 		$127K Sell
2,424
-62,522
-96% -$3.74M ﹤0.01% 1772
2025
Q3 		$4.21M Buy
64,946
+42,477
+189% +$2.44M 0.12% 146
2025
Q2 		$1.09M Sell
22,469
-1,886
-8% -$73K 0.03% 507
2025
Q1 		$829K Buy
24,355
+18,902
+347% +$801K 0.02% 579
2024
Q4 		$215K Buy
5,453
+4,544
+500% +$215K ﹤0.01% 1667
2024
Q3 		$42.7K Sell
909
-1,774
-66% -$90K ﹤0.01% 2810
2024
Q2 		$145K Sell
2,683
-1,749
-39% -$101K ﹤0.01% 2321
2024
Q1 		$302K Buy
4,432
+1,016
+30% +$72.7K 0.01% 1161
2023
Q4 		$214K Sell
3,416
-855
-20% -$47.3K ﹤0.01% 2053
2023
Q3 		$194K Sell
4,271
-9,440
-69% -$488K 0.01% 1451
2023
Q2 		$770K Sell
13,711
-4,904
-26% -$278K 0.03% 680
2023
Q1 		$842K Buy
18,615
+15,219
+448% +$739K 0.03% 535
2022
Q4 		$138K Sell
3,396
-23,594
-87% -$1.25M 0.01% 1577
2022
Q3 		$1.76M Buy
26,990
+9,128
+51% +$662K 0.03% 471
2022
Q2 		$1.08M Buy
17,862
+11,292
+172% +$664K 0.02% 643
2022
Q1 		$413K Buy
6,570
+3,485
+113% +$219K ﹤0.01% 1263
2021
Q4 		$234K Buy
3,085
+173
+6% +$15.1K ﹤0.01% 1636
2021
Q3 		$326K Sell
2,912
-9,149
-76% -$1.15M 0.01% 1315
2021
Q2 		$1.95M Sell
12,061
-33,509
-74% -$4.08M 0.05% 313
2021
Q1 		$5.55M Buy
45,570
+42,265
+1,279% +$6.38M 0.09% 192
2020
Q4 		$506K Buy
3,305
+2,717
+462% +$321K 0.02% 985
2020
Q3 		$49K Buy
588
+345
+142% +$30.6K ﹤0.01% 3547
2020
Q2 		$18K Buy
+243
New +$14.2K ﹤0.01% 3729
2020
Q1 		– Sell
-1,016
Closed -$62K – 3161
2019
Q4 		$62K Buy
1,016
+969
+2,062% +$52.9K 0.01% 1201
2019
Q3 		$2K Sell
47
-241
-84% -$11.5K ﹤0.01% 3664
2019
Q2 		$14K Sell
288
-860
-75% -$34.4K ﹤0.01% 2372
2019
Q1 		$41K Sell
1,148
-31,354
-96% -$1.08M ﹤0.01% 1864
2018
Q4 		$929K Buy
32,502
+31,027
+2,104% +$1.08M 0.07% 283
2018
Q3 		$65K Buy
1,475
+822
+126% +$43K ﹤0.01% 1594
2018
Q2 		$38K Sell
653
-1,879
-74% -$107K ﹤0.01% 2013
2018
Q1 		$116K Buy
+2,532
New +$105K 0.01% 1170
2017
Q4 		– Sell
-1,387
Closed -$25K – 3582
2017
Q3 		$25K Buy
+1,387
New +$25.1K ﹤0.01% 2577
2017
Q1 		– Sell
-479
Closed -$10K – 3169
2016
Q4 		$10K Buy
+479
New +$8.95K ﹤0.01% 2633

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Tower Research Capital (TRC)'s CRSP Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its CRISPR Therapeutics (CRSP) stake by 119% in Q1 2026, buying an estimated $152K and bringing the position to 5,298 shares worth $252K. The position accounts for 0.01% of the portfolio, ranked #1437.

Tower Research Capital (TRC) first reported a position in CRSP in Q4 2016 and has held it in 34 quarters since. The position peaked at $5.55M in Q1 2021. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Tower Research Capital (TRC) held 5,298 shares of CRISPR Therapeutics worth $252K as of Q1 2026.
  • Tower Research Capital (TRC) bought 2,874 CRISPR Therapeutics shares in Q1 2026, an estimated $152K.
  • CRISPR Therapeutics made up 0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #1437 holding.
  • Tower Research Capital (TRC) first reported a position in CRISPR Therapeutics in Q4 2016 and has held it in 34 quarters since.
  • Tower Research Capital (TRC)'s CRISPR Therapeutics position peaked at $5.55M in Q1 2021.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.